Correlation Between Serum Tumor Marker Levels and Connective Tissue Disease-Related Interstitial Lung Disease

References

• Fischer A, Du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380(9842):689–698. doi:10.1016/S0140-6736(12)61079-4
   PubMed Web of Science ®Google Scholar
• Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583–1591. doi:10.1002/art.27405
   PubMed Web of Science ®Google Scholar
• Atzeni F, Gerardi MC, Barilaro G, Masala IF, Benucci M, Sarzi-Puttini P. Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. Expert Rev Clin Immunol. 2018;14(1):69–82. doi:10.1080/1744666X.2018.1411190
   PubMed Web of Science ®Google Scholar
• Schnabel A, Hellmich B, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis. Curr Rheumatol Rep. 2005;7(2):99–105. doi:10.1007/s11926-005-0061-4
   PubMedGoogle Scholar
• Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352:h6819. doi:10.1136/bmj.h6819
   PubMed Web of Science ®Google Scholar
• Oguz EO, Kucuksahin O, Turgay M, et al. Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study. Clin Rheumatol. 2016;35(3):663–666. doi:10.1007/s10067-015-3167-8
   PubMed Web of Science ®Google Scholar
• Lee JS, Lee EY, Ha Y-J, Kang EH, Lee YJ, Song YW. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res Ther. 2019;21(1):58. doi:10.1186/s13075-019-1835-9
   PubMed Web of Science ®Google Scholar
• Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002;165(3):378–381. doi:10.1164/ajrccm.165.3.2107134
   PubMed Web of Science ®Google Scholar
• Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol. 2004;31(6):1112–1120.
   PubMed Web of Science ®Google Scholar
• Hant FN, Ludwicka-Bradley A, Wang H-J, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol. 2009;36(4):773–780. doi:10.3899/jrheum.080633
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold A-M, Tennøe AH, Garen T, et al. High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis. Chest. 2016;150(2):299–306. doi:10.1016/j.chest.2016.03.004
   PubMed Web of Science ®Google Scholar
• Doyle TJ, Patel AS, Hatabu H, et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med. 2015;191(12):1403–1412. doi:10.1164/rccm.201411-1950OC
   PubMed Web of Science ®Google Scholar
• Elhai M, Avouac J, Allanore Y. Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: where do we stand? Semin Arthritis Rheum. 2020;50(3):480–491. doi:10.1016/j.semarthrit.2020.01.006
   PubMed Web of Science ®Google Scholar
• Duffy MJ, O’Byrne K. Tissue and blood biomarkers in lung cancer: a review. Adv Clin Chem. 2018;86:1–21. doi:10.1016/bs.acc.2018.05.001
   PubMed Web of Science ®Google Scholar
• Silsirivanit A. Glycosylation markers in cancer. Adv Clin Chem. 2019;89:189–213. doi:10.1016/bs.acc.2018.12.005
   PubMed Web of Science ®Google Scholar
• Zheng M, Lou A, Zhang H, Zhu S, Yang M, Lai W. Serum KL-6, CA19-9, CA125 and CEA are diagnostic biomarkers for rheumatoid arthritis-associated interstitial lung disease in the Chinese population. Rheumatol Ther. 2021;8(1):517–527. doi:10.1007/s40744-021-00288-x
   PubMed Web of Science ®Google Scholar
• Wang T, Zheng X-J, Ji Y-L, Liang Z-A, Liang B-M. Tumour markers in rheumatoid arthritis-associated interstitial lung disease. Clin Exp Rheumatol. 2016;34(4):587–591.
   PubMed Web of Science ®Google Scholar
• Shi L, Han X-L, Guo H-X, et al. Increases in tumor markers are associated with primary sjögren’s syndrome-associated interstitial lung disease. Ther Adv Chronic Dis. 2020;11:2040622320944802. doi:10.1177/2040622320944802
   Web of Science ®Google Scholar
• Wong RCW, Klingberg S, Wilson R. CA15-3 and cancer associated serum antigen assays are alternatives to the KL-6 assay for measuring serum MUC-1 levels in patients with interstitial lung disease associated with polymyositis/dermatomyositis. J Rheumatol. 2002;29(9):2021–2022;author reply 2022.
   Web of Science ®Google Scholar
• Celeste S, Santaniello A, Caronni M, et al. Carbohydrate antigen 15.3 as a serum biomarker of interstitial lung disease in systemic sclerosis patients. Eur J Intern Med. 2013;24(7):671–676. doi:10.1016/j.ejim.2013.04.004
   PubMed Web of Science ®Google Scholar
• Dai H, Liu J, Liang L, et al. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers. Respirology. 2014;19(5):707–713. doi:10.1111/resp.12317
   PubMed Web of Science ®Google Scholar
• Dobashi N, Fujita J, Ohtsuki Y, et al. Elevated serum and BAL cytokeratin 19 fragment in pulmonary fibrosis and acute interstitial pneumonia. Eur Respir J. 1999;14(3):574–578. doi:10.1034/j.1399-3003.1999.14c15.x
   PubMed Web of Science ®Google Scholar
• Sargin G, Köse R, Şentürk T. Tumor-associated antigens in rheumatoid arthritis interstitial lung disease or malignancy? Arch Rheumatol. 2018;33(4):431–437. doi:10.5606/ArchRheumatol.2018.6691
   PubMed Web of Science ®Google Scholar
• Gui X, Ma M, Ding J, et al. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis. Rheumatology. 2021. doi:10.1093/rheumatology/keaa843
   PubMed Web of Science ®Google Scholar
• Mylin AK, Abildgaard N, Johansen JS, et al. Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma. Leuk Lymphoma. 2015;56(9):2650–2659. doi:10.3109/10428194.2015.1004168
   PubMed Web of Science ®Google Scholar
• Thongsom S, Chaocharoen W, Silsirivanit A, et al. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma. Tumour Biol. 2016;37(7):9451–9463. doi:10.1007/s13277-016-4838-z
   PubMedGoogle Scholar
• Korthagen NM, van Moorsel CHM, Zanen P, Ruven HJ, Grutters JC. Evaluation of circulating YKL-40 levels in idiopathic interstitial pneumonias. Lung. 2014;192(6):975–980. doi:10.1007/s00408-014-9647-9
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Distler O, Ryerson CJ, et al. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis. 2021;80(2):143–150. doi:10.1136/annrheumdis-2020-217230
   PubMed Web of Science ®Google Scholar
• Kanazawa H, Yoshikawa T, Yamada M, et al. CYFRA 21-1, a cytokeratin subunit 19 fragment, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Clin Sci. 1998;94(5):531–535. doi:10.1042/cs0940531
   Web of Science ®Google Scholar
• Vercauteren IM, Verleden SE, McDonough JE, et al. CYFRA 21.1 in bronchoalveolar lavage of idiopathic pulmonary fibrosis patients. Exp Lung Res. 2015;41(8):459–465. doi:10.3109/01902148.2015.1073407
   PubMed Web of Science ®Google Scholar